Fernando Aleman obtained his PharmD degree at University of Granada and his PhD at University of Murcia. After postdoctoral training at University of California San Diego and the Scripps Research Institute, he leverages his pharmaceutical and industry background to provide medical oversight and strategic direction for all development activities. He serves as the pharmaceutical point of contact for external stakeholders.

Ana Moreno, the CEO, obtained her PhD from the Bioengineering Department at UCSD. She has over 6+ years of experience in molecular biology and gene therapy. In addition, she is the co-inventor on two patents that have been licensed to Navega. She has been working on developing this therapy for the last 3 years.